Novartis, the global leader in KIT+ GIST therapy, has been working with health care professionals and patients worldwide to help improve the treatment of KIT+ GIST. Although the tolerability and safety of the new oral tyrosine kinase inhibitor class of agents in general is much improved over past treatments and traditional chemotherapy for GIST, these agents can still be associated with adverse reactions.

In fact, the majority of patients taking these agents will experience side effects at some time. In clinical trials, most patients continued treatment despite side effects. And even though the majority of these side effects are mild to moderate in severity, they still may require supportive care.

• Some adverse reactions may resolve with supportive care, while others may require discontinuation or dosage adjustment^1,2
• Whenever possible, continue daily dosing to help maintain ongoing suppression of the tyrosine kinase receptor KIT

*This information is provided as a courtesy to healthcare professionals to assist in their decisions with respect to choice of medicine for supportive care and any potential drug interactions. Before prescribing any treatment, please see the full prescribing information for the specific agent(s) you are considering.